5AM Venture Management LLC Makes New Investment in Maplight Therapeutics, Inc. $MPLT

5AM Venture Management LLC bought a new position in Maplight Therapeutics, Inc. (NASDAQ:MPLT - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 950,011 shares of the company's stock, valued at approximately $34,048,394. Maplight Therapeutics comprises about 0.0% of 5AM Venture Management LLC's investment portfolio, making the stock its largest position. 5AM Venture Management LLC owned approximately 2.23% of Maplight Therapeutics as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of MPLT. Fcpm Iii Services B.V. bought a new position in Maplight Therapeutics in the 4th quarter worth about $56,672,000. T. Rowe Price Investment Management Inc. bought a new position in Maplight Therapeutics in the 4th quarter worth about $49,154,000. Goldman Sachs Group Inc. bought a new position in Maplight Therapeutics in the 4th quarter worth about $34,026,000. BlackRock Inc. bought a new position in Maplight Therapeutics in the 2nd quarter worth about $36,741,000. Finally, Nan Fung Group Holdings Ltd bought a new position in Maplight Therapeutics in the 2nd quarter worth about $34,809,708.

Maplight Therapeutics Price Performance

MPLT opened at $12.60 on Friday. The company has a market capitalization of $584.39 million and a price-to-earnings ratio of -0.30. Maplight Therapeutics, Inc. has a 1-year low of $9.10 and a 1-year high of $40.43. The business has a 50 day moving average price of $23.97 and a two-hundred day moving average price of $24.09.

Maplight Therapeutics (NASDAQ:MPLT - Get Free Report) last released its earnings results on Thursday, August 13th. The company reported ($1.32) earnings per share for the quarter, topping analysts' consensus estimates of ($1.40) by $0.08. Equities analysts expect that Maplight Therapeutics, Inc. will post -5.12 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider James Woodruff Lillie sold 22,082 shares of the business's stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $12.54, for a total value of $276,908.28. Following the sale, the insider directly owned 202,380 shares in the company, valued at $2,537,845.20. The trade was a 9.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Troy Cox bought 15,620 shares of the company's stock in a transaction that occurred on Tuesday, July 28th. The stock was acquired at an average price of $9.52 per share, for a total transaction of $148,702.40. Following the completion of the acquisition, the director directly owned 15,620 shares in the company, valued at approximately $148,702.40. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 3.80% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on MPLT. BMO Capital Markets began coverage on shares of Maplight Therapeutics in a research report on Monday, July 20th. They issued an "outperform" rating and a $46.00 target price for the company. Weiss Ratings restated a "sell (d-)" rating on shares of Maplight Therapeutics in a research report on Monday, July 13th. Morgan Stanley reaffirmed an "equal weight" rating and issued a $21.00 price target (down from $34.00) on shares of Maplight Therapeutics in a research note on Tuesday, July 28th. Lifesci Capital upgraded shares of Maplight Therapeutics to a "strong-buy" rating in a report on Thursday, May 14th. Finally, Needham & Company LLC raised their price objective on shares of Maplight Therapeutics from $42.00 to $45.00 and gave the company a "buy" rating in a research note on Friday, July 10th. Four investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $29.67.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source